MMS Named a Top Workplace for the 4th Year! Discover how we’re empowering employees and driving innovation. Learn more
BANGALORE, India (1/12/2023) – MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India. This award is based on anonymous feedback from a survey sent out to employees and measures the quality of employee experience, the strength of leadership, the quality … MMS Named a Great Place to Work in India
CANTON, Mich. (11/21/2022) – MMS Holdings, a data-focused contract research organization (CRO), has been named a 2022 award winner of the Michigan Top Workplaces by the Detroit Free Press Top Workplaces. This is the second year that MMS has been recognized with this honor. This award is based on feedback from a confidential survey sent out … MMS Named Michigan Top Workplace For The Second Consecutive Year
The TOGETHER Trial, which uses an Electronic Data Capture (EDC database) system designed, built, and maintained by MMS Holdings, a data-focused contract research organization (CRO), won the Society for Clinical Trial’s annual Trial of the Year Award for 2021.
MMS Holdings Inc. (“MMS” or the “Company”), a leading data-focused contract research organization (“CRO”), today announced that Lindsay Goldberg, a leading family and founder-focused private equity firm, has completed an investment in the Company alongside MMS Founder and CEO, Dr. Uma Sharma, who will maintain a significant ownership interest. The partnership will help MMS expand its award-winning services to pharma and biotech companies and extend MMS’ leadership in data-focused clinical research services
MMS Holdings (MMS), an award-winning, data-focused contract research organization (CRO), announced today that it has been selected by MAPS Public Benefit Corporation (MAPS PBC) as its contract research organization for the development of a New Drug Application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD). This announcement comes on PTSD Awareness Day as the confirmatory Phase 3 trial MAPP2, the second of two Phase 3 trials conducted by MAPS PBC, finished enrollment in early May.
MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to announce a strategic partnership with Medidata, a Dassault Systèmes company, to provide clients a full range of solutions for clinical data management (CDM) and decentralized clinical trial solutions (DCTs), including Medidata’s unified platform and Rave EDC (Electronic Data Capture).
MMS Holdings Inc. (MMS) – an award-winning, data-focused contract research organization (CRO) – announced a collaboration with THREAD® as its partner of choice for its decentralized clinical trials platform (DCT) and DCT-enabled services. THREAD’s next-generation DCT technology enables faster, more efficient clinical trials while improving access for research participants with higher quality data capture across the life cycle of a study.
MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, biopharma executive, as Principal Medical Director of Global Drug Safety and Pharmacovigilance to its team.
CANTON, Mich. (2/2/2022) – MMS Holdings, a Data CRO, was recognized in the 2022 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates. MMS, a minority and woman-owned business in Canton, was the only Michigan Pharma organization on the national list.
MMS Holdings announced a restructuring of their consulting services with the launch of a Project Advisory Services Unit to meet the needs of many small to mid-sized organizations in immediate, short and long-term needs for senior-level guidance, specialized consulting, and advisory services.
MMS Holdings is pleased to announce its selection as Best Contract Research Organization – Specialist Providers in the 2021 Scrip Awards. The Scrip Awards, held annually by London-based Informa Pharma Intelligence, honors outstanding achievements of organizations in the pharmaceutical, biotech and allied industries.
Former Astellas Pharma VP of Biostatistics Joins MMS as Principal Advisor of Biostatistics and Submissions Planning. Dr. Chartier has held positions at Astellas Pharma, Novartis, Wyeth, Pfizer, and United BioSource Corporation across various statistics, biometrics, and biostatistics functions.